Dineshkumar Thakur, MD
Cardiovascular Disease · Vallejo, CANPI 1245243716
Payments from drug & device makers
Across 198 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$898
- Novartis$401
- Johnson & Johnson$343
- AstraZeneca$304
- Boehringer Ingelheim$255
- Amgen$250
- plus $2K from 35 others
What the payments were for
- Food & beverage$4,347100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 37 | $898 |
| Novartis | 20 | $401 |
| Johnson & Johnson(2 entities) | 18 | $343 |
| AstraZeneca(2 entities) | 17 | $304 |
| Boehringer Ingelheim | 15 | $255 |
| Amgen | 11 | $250 |
| E.r. Squibb & Sons, L.L.C. | 8 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
| Eisai Inc. | 5 | $116 |
| Novo Nordisk | 1 | $116 |
| Agios Pharmaceuticals, Inc. | 3 | $107 |
| Biotronik Inc. | 1 | $95 |
| Pfizer | 5 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
| Daiichi Sankyo Inc. | 4 | $85 |
| Bristol Myers Squibb | 4 | $80 |
| Edwards Lifesciences | 3 | $73 |
| Scpharmaceuticals Inc. | 3 | $69 |
| Caris MPI, Inc. | 3 | $60 |
| Emmaus Medical, Inc. | 6 | $59 |
| AbbVie | 2 | $52 |
| Boston Scientific | 1 | $50 |
| Sobi, Inc | 2 | $47 |
| Beigene USA, Inc. | 2 | $36 |
| Seagen Inc. | 1 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Taiho Oncology, Inc. | 1 | $33 |
| Servier Pharmaceuticals LLC | 2 | $32 |
| Bayer | 1 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Philips North America LLC | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Sanofi | 1 | $23 |
| Exelixis Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Novocure Inc. | 1 | $20 |
| Tempus AI, Inc | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
How this compares
$4,360 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 247 | $308,518 |
| EntrestoSacubitril/Valsartan | 162 | $157,563 |
| FarxigaDapagliflozin Propanediol | 105 | $97,268 |
| XareltoRivaroxaban | 32 | $37,149 |
| JardianceEmpagliflozin | 29 | $24,215 |
| DapagliflozinDapagliflozin Propanediol | 26 | $13,851 |
| Praluent PenAlirocumab | 13 | $13,061 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 49 | $3,198 |
| Ezetimibe | 72 | $2,539 |
| Valsartan | 66 | $2,506 |
| Metoprolol Succinate | 169 | $2,438 |
| Amiodarone Hcl | 34 | $2,273 |
| Atorvastatin Calcium | 289 | $2,252 |
| Isosorbide Dinitrate | 32 | $2,131 |
| Carvedilol | 218 | $1,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $90 | $308,518247 claims |
| NovartisEntresto | $401 | $157,563162 claims |
| AstraZenecaFarxiga | $304 | $97,268105 claims |
| Johnson & JohnsonXarelto | $343 | $37,14932 claims |
| Boehringer IngelheimJardiance | $255 | $24,21529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Vallejo
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.